Cargando…

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies

BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spagnolo, Francesco, Ghiorzo, Paola, Orgiano, Laura, Pastorino, Lorenza, Picasso, Virginia, Tornari, Elena, Ottaviano, Vincenzo, Queirolo, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303458/ https://www.ncbi.nlm.nih.gov/pubmed/25653539 http://dx.doi.org/10.2147/OTT.S39096

Ejemplares similares

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry
por: Bruno, William, et al.
Publicado: (2016)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
por: Vanni, Irene, et al.
Publicado: (2020)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020)

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2017)

Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2018)

Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients
por: Ciccarese, Giulia, et al.
Publicado: (2020)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Pancreatic Cancer: From Genetic Mechanisms to Translational Challenges
por: Pastorino, Lorenza, et al.
Publicado: (2023)

Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting
por: Vanni, Irene, et al.
Publicado: (2023)

TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear
por: Monti, Paola, et al.
Publicado: (2017)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
por: Boutros, Andrea, et al.
Publicado: (2020)

Identification, genetic testing, and management of hereditary melanoma
por: Leachman, Sancy A., et al.
Publicado: (2017)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
por: Pastorino, Lorenza, et al.
Publicado: (2022)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Insights into Mechanisms of Tumorigenesis in Neuroendocrine Neoplasms
por: Pastorino, Lorenza, et al.
Publicado: (2021)

Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI)
por: Vanni, Irene, et al.
Publicado: (2020)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2020)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
por: Aglietta, Massimo, et al.
Publicado: (2021)

BRAF Gene and Melanoma: Back to the Future
por: Ottaviano, Margaret, et al.
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1
por: Pastorino, Lorenza, et al.
Publicado: (2020)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
por: Yang, Gang, et al.
Publicado: (2021)

HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
por: Sottile, Rosa, et al.
Publicado: (2015)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor
por: Corazao-Rozas, Paola, et al.
Publicado: (2013)

Functional analysis of a CDKN2A 5’UTR germline variant associated with pancreatic cancer development
por: Bruno, William, et al.
Publicado: (2017)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dcaacgnb3depoks20o6n09a6a4